Amundi Purchases 6,559,261 Shares of Kenvue Inc. $KVUE

Amundi boosted its position in shares of Kenvue Inc. (NYSE:KVUE) by 82.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,509,890 shares of the company’s stock after buying an additional 6,559,261 shares during the period. Amundi’s holdings in Kenvue were worth $305,446,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Baird Financial Group Inc. boosted its position in shares of Kenvue by 10.6% during the 2nd quarter. Baird Financial Group Inc. now owns 781,062 shares of the company’s stock worth $16,348,000 after acquiring an additional 75,088 shares in the last quarter. Guggenheim Capital LLC lifted its stake in Kenvue by 33.3% during the second quarter. Guggenheim Capital LLC now owns 255,061 shares of the company’s stock worth $5,338,000 after purchasing an additional 63,736 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Kenvue by 32.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 9,576 shares of the company’s stock valued at $200,000 after purchasing an additional 2,321 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Kenvue by 11.0% in the 2nd quarter. Invesco Ltd. now owns 17,818,771 shares of the company’s stock valued at $372,947,000 after purchasing an additional 1,759,065 shares in the last quarter. Finally, Independent Franchise Partners LLP increased its stake in shares of Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock valued at $654,388,000 after purchasing an additional 21,886,537 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Jefferies Financial Group reduced their price objective on Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Monday, October 27th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Deutsche Bank Aktiengesellschaft set a $18.00 price target on shares of Kenvue in a report on Friday, October 24th. Rothschild & Co Redburn upgraded shares of Kenvue from a “neutral” rating to a “buy” rating and lowered their price objective for the stock from $22.50 to $22.00 in a research report on Friday, September 26th. Finally, Citigroup cut their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $20.23.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $16.92 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The firm has a market cap of $32.42 billion, a PE ratio of 22.56 and a beta of 0.60. The firm’s fifty day moving average is $16.09 and its 200-day moving average is $19.36.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. The business had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.Kenvue’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.9%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.